𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Generation of killer lymphocytes and adoptive immunotherapy for human cancer

✍ Scribed by B. Sharma

Publisher
Springer-Verlag
Year
1980
Tongue
English
Weight
366 KB
Volume
7
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Adoptive immunotherapy for advanced canc
Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes
✍ Soda, Hiroaki; Koda, Keiji; Yasutomi, Jun; Oda, Kenji; Takiguchi, Nobuhiro; Sait πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 219 KB πŸ‘ 2 views

## Background and Objectives: We evaluated the clinical efficacy of adoptive immunotherapy using in vitro activated cytotoxic T lymphocytes (CTL) in the treatment of patients with advanced cancer. Methods: CTL were induced with the mixed lymphocyte and tumor cell culture method, in which lymphocyte

Potential of human Ξ³Ξ΄ T lymphocytes for
Potential of human Ξ³Ξ΄ T lymphocytes for immunotherapy of cancer
✍ Dieter Kabelitz; Daniela Wesch; Elke Pitters; Margot ZΓΆller πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 92 KB

## Abstract T lymphocytes are classified into 2 subsets based on their T‐cell receptor (TCR) expression. The vast majority of T cells expresses an Ξ±Ξ² TCR heterodimer. These Ξ±Ξ² T cells recognize antigenic peptides presented by MHC class I (for CD8^+^ T cells) or MHC class II molecules (for CD4^+^ T

Rapid enrichment of human papillomavirus
Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer
✍ Annemieke de Jong; Jeanette M. van der Hulst; Gemma G. Kenter; Jan Wouter Drijfh πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 196 KB

## Abstract The majority of cervical cancers are caused by human papillomavirus type 16 (HPV16). Cervical cancer is associated with an ineffective host immune response against the HPV16 oncoproteins, characterized by the lack of the strong E6‐specific T‐helper type 1 (Th1) immunity that is generall